The class of drugs called SGLT-2 inhibitors encompasses several different medications that are intended to treat adults with Type-2 diabetes. While there are some benefits to these medications, each drug has its own serious side effects that have caused complications. These side effects can be serious and can lead to death in severe cases. Since these drugs are relatively new, many side effects are now being revealed after years of the drugs being prescribed. As a result, there have been numerous lawsuits against the manufacturers of these drugs seeking financial compensation for the harms that have been suffered. Given the large range of harmful complications, there are many different possible lawsuits against drugmakers, and new causes of action are still being revealed.
Patients who have suffered harmful side effects after taking an SGLT-2 inhibitor will be looking for a drug injury law firm for legal assistance. Broughton Partners connects personal injury law firms with SGLT-2 inhibitor lawsuit leads and other drug injury leads. The leads we deliver to law firms are case-ready and pre-qualified. Law firms looking for more SGLT-2 inhibitor lawsuit leads can work with Broughton Partners and start receiving SGLT-2 inhibitor lawsuit leads that fit their specific case criteria.
How Do We Find SGLT-2 Inhibitor Lawsuit Leads?
Our experienced in-house marketing team begins by targeting and connecting with victims that are searching for information about proton pump inhibitors and if they have a lawsuit. We then begin tracking SGLT-2 Inhibitor lawsuit leads online with our industry-leading case-acquisition platform as soon as potential SGLT-2 Inhibitor plaintiffs show interest or call. Our system is constantly being updated and optimized so that only qualified leads are being delivered to law firms.
Our in-house call center is open and working 24 hours with multi-lingual specialists. Each of our intake associates is highly trained and knows how to handle intake sessions with quality and compassion. The SGLT-2 Inhibitor cases we come into contact with will be assessed by our in-house call center staff using customized questions and a qualification process that is based on your law firm’s SGLT-2 Inhibitor case criteria.
When our team finds a qualified SGLT-2 Inhibitor lawsuit lead, we then gather appropriate case documents that your law firm will need to start working on the case right away.
Get More Than Just SGLT-2 Inhibitor Leads
Broughton Partners doesn’t just deliver retained SGLT-2 Inhibitor plaintiffs, we go further by providing SGLT-2 Inhibitor lawsuit leads ready with case documents such as hospital files and product information. We want to save your law firm’s time and provide everything you need to start working the case immediately. The SGLT-2 Inhibitor lawsuit leads that are provided by Broughton Partners are real victims who have legitimate SGLT-2 Inhibitor cases.
Finding SGLT-2 Inhibitor lawsuit leads can be difficult, especially qualified leads that have been reviewed for drug injury lawsuit eligibility. Broughton Partners will perform the time-consuming work of reviewing potential SGLT-2 Inhibitor leads and will only provide you with cases that meet your criteria.
What Are SGLT-2 Inhibitors?
Those who suffer from Type 2 diabetes have bodies that do not produce a sufficient amount of insulin. The lack of insulin means that blood glucose remains at high levels, building up in the bloodstream. Higher blood sugar levels have a variety of health effects, including kidney damage and heart disease.
Patients suffering from Type 2 diabetes need to find ways to counteract the effects of insufficient insulin. One way of achieving this is by administering an SGLT-2 inhibitor to keep the kidneys from reabsorbing glucose into the blood. If the drug works as intended, an SGLT-2 inhibitor can contribute to a lowering of blood sugar levels.
How SGLT-2 Inhibitors Work
Reabsorption of glucose into the kidneys requires certain facilitators and conditions in order to occur. One thing that aids in this absorption is SGLT-2. This is a protein that is found in the kidneys that acts as a transporter. It is responsible for nearly all of the glucose reabsorption. Thus, a medication that can act against the SGLT and its role in this process can help lower blood sugar.
The specific mechanism whereby an SGLT-2 inhibitor works is by targeting this protein. SGLT-2 inhibitors go after the transporter that brings the glucose into the blood. When that happens, glucose is not reabsorbed into the bloodstream. Instead, it exits the body through urine.
Types of SGLT-2 Inhibitors
Under the SGLT-2 umbrella, there are many different types of medications that act in different ways. Here are some of the SGLT-2 medications that are available in the marketplace and their manufacturers:
- Invokana (Janssen Pharmaceutical)
- Farxiga (AstraZeneca)
- Jardiance (Boehringer Ingelheim)
- Glyxambi (Boehringer Ingelheim)
- Synjardy (Boehringer Ingelheim)
- Xigduo XR (AstraZeneca)
Invokana has been the market leader in this space. Previously, its sales comprised over half of the total sales for this type of medication. However, reports of some of the complications caused by Invokana have resulted in a shift to rival drugs. Jardiance, made by Boehringer Ingelheim in partnership with Eli Lilly, has picked up market share from Invokana, cutting Invokana’s market share below 50 percent. As detailed below, many of the more severe side effects have been associated with Invokana. The publicity has begun to cause shifts in the marketplace.
As this class of drugs gains in popularity, the market continues to grow at roughly 15 percent annually. According to the CDC, there are roughly 100 million people in the U.S. who have been diagnosed with diabetes or pre-diabetes, and the rate continues to grow. Thus, the number of people (and possible plaintiffs) who have taken SGLT-2 inhibitors is significant. SGLT-2 inhibitors are now being approved by the FDA for other uses besides treating Type 2 diabetes.
Side Effects of SGLT-2 Inhibitors
While SGLT-2 inhibitors have gained users since they were first approved by the FDA, this class of drugs is not without its side effects. First, it is important to note that not all drugs in this class are the same. Different SGLT-2 inhibitors have different mechanisms of action. It follows that the side effects that are associated with Invokana may not be the same as those that result from Jardiance.
Invokana has made headlines with reports of the complications that patients have experienced. Specifically, there are four major side effects that have been reported by patients.
- Increased risk of amputation – Patients who are taking Invokana have required amputations of their lower extremities at nearly double the rate of diabetics who are not taking the drug. In fact, the FDA now requires a black box warning, which is the most severe category of warning alerting consumers to the dangers of a medication
- Kidney damage – In some cases, Invokana has been reported to cause kidney failure or partial loss of kidney function. While this complication is relatively rare, the effects of it are severe as it has caused several deaths.
- Diabetic ketoacidosis – Invokana acts to lower blood sugar. Sometimes, when the body cannot look to sugars and glucose as fuel, it will attempt to use fat for this purpose. This can result in the production of a harmful and toxic chemical in the body that can cause coma or death.
- Fournier Gangrene – A potentially life-threatening skin infection that affects the genital and perineal areas of the body can be caused by the SGLT2 inhibitors used to treat diabetes.
Jardiance has its own side effects that are no less dangerous. The medication also increases the risk of gangrene and subsequent amputations. Jardiance can also cause a rare gangrenous infection in the genitals. The FDA issued a safety communication in 2018 warning patients of this possibility. Although it is rare, some patients on Jardiance can also develop a flesh-eating bacterial infection.
Farxiga has many of the same side effects at Jardiance and Invokana. While these side effects do not impact every patient that takes these drugs, when they do, the harm to the patient can be severe.
Lawsuits Against SGLT-2 Manufacturers
Patients who have experienced these side effects can file claims against the makers of these drugs to compensate them for the injuries that they have suffered. Plaintiffs can receive payment for not only medical bills, but also for lost wages and pain and suffering. Given the severity of the negative effects of these medications, compensation for pain and suffering can be high.
Many of these lawsuits have yet to be filed. SGLT-2 inhibitors are still a relatively new class of drugs, having initially been approved by the FDA in 2013. This means that many patients may still experience side effects or are still within the statute of limitations that places time limitations on when they can file their suit. Many of the patients who have suffered harm after taking these drugs experience them shortly after beginning the drug regimen.
As of 2018, there were over 1,000 lawsuits that were filed against Janssen for Invokana injuries. These lawsuits were part of multi-district litigation in federal court in New Jersey, where the company is headquartered. At the time, Johnson & Johnson entered into a settlement agreement covering most of the lawsuits that were filed against it. While the amount of the settlement has not been released, it is likely that damages were substantial, especially in light of other settlements involving Type 2 diabetes drugmakers that reached billions of dollars. The settlement established a fund to compensate those who were injured by the drug.
Even though some Invokana lawsuits have been settled by Johnson & Johnson, there are still hundreds of lawsuits relating to Invokana that are still outstanding in federal court. The plaintiffs are also filing cases against the manufacturer in state court. For example, there are many cases pending in Pennsylvania, which is a jurisdiction where juries that may make large awards to plaintiffs reside.
There are also numerous cases against Boehringer Ingelheim and Eli Lilly for harm suffered by those taking Jardiance. Many of these cases are still being filed since the FDA did not issue any warnings about the medication until last year. These cases are still open and have not yet been settled or litigated. Much of the research and studies about Jardiance and Farxiga are still being released. This will likely be a growing area for lawsuits, especially as these medications are now taking market share from Invokana.
SGLT-2 Inhibitor Lawsuits Are Being Filed by Injured Patients
While some of the lawsuits have been settled, SGLT-2-related lawsuits are by no means finished. There are many drugs in this class and new side effects are becoming apparent as these drugs increase in market maturity. New FDA releases have spurred potential plaintiffs into action as they are able to associate the harm that they have suffered from the emerging risks of these drugs. When potential plaintiffs know that they are not alone in having suffered their injuries, they are more likely to file a lawsuit.
As already noted, due to the severity of some of the side effects, damages associated with these complications can be severe. SGLT-2 lawsuits are likely to be around and will continue to be filed for years to come.
Would you like to represent more claimants injured by SGLT-2 Inhibitors?
Bringing in new SGLT-2 Inhibitor cases in a cost-effective manner without sacrificing the needs of your current clients and the daily demands of your practice is a challenge at best. Broughton Partners is here to give you a competitive advantage by connecting you with qualified SGLT-2 Inhibitor lawsuit leads that are ready and need your representation today.
Start reaching your goals and take your practice to the next level with new SGLT-2 Inhibitor lawsuit leads. Call Broughton Partners today at (855) 463-1735, or contact us for your free consultation. Together we can ensure there is No Claimant without a Claim.
- FDA. “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, U.S. Food & Drug Administration, https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes. Accessed May 30, 2019.
- Mayo Clinic. “Canagliflozin (Oral Route)”, Mayo Clinic, https://www.mayoclinic.org/drugs-supplements/canagliflozin-oral-route/side-effects/drg-20060957?p=1. Accessed May 30, 2019.
- Mahakpreet Singh and Anoop Kumar. “Risks Associated with SGLT2 Inhibitors: An Overview.”, Curr Drug Saf, https://www.ncbi.nlm.nih.gov/pubmed/29485006. Accessed May 30, 2019.
- MedicineNet. “What are SGLT2 inhibitors?”, MedicineNet, https://www.medicinenet.com/sglt2_inhibitors_type_2_diabetes_drug_class/article.htm. Accessed May 30, 2019.
- Bersoff-Matcha et al. “Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases”, Annals of Internal Medicine, https://annals.org/aim/article-abstract/2732837/fournier-gangrene-associated-sodium-glucose-cotransporter-2-inhibitors-review-spontaneous. Accessed May 30, 2019.